GPD1L

Across TCGA pan-cancer cohorts, GPD1L mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPD1L data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GPD1L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GPD1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where GPD1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.874	0.660	<.001	80	view →
CCRCC	DFS	Median	III,IV	0.777	0.409	.004	28	view →
COAD	DFS	Quartile	All	1.000	0.889	.035	18	view →
HNSC	DFS	Quartile	II,III,IV	0.874	1.000	.005	10	view →
LUAD	OS	Quartile	II,III,IV	0.806	0.412	.008	9	view →
UCEC	DFS	Median	III,IV	0.445	0.904	.037	4	view →
LSCC	OS	Tertile	All	1.000	0.678	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPD1L–PDAC (DFS)

Open the PDAC breakdown →